Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Lineage Cell Therapeutics (LCTX) Equity Ratio (2016 - 2025)

Lineage Cell Therapeutics (LCTX) has 16 years of Equity Ratio data on record, last reported at 0.4 in Q4 2025.

  • For Q4 2025, Equity Ratio fell 42.84% year-over-year to 0.4; the TTM value through Dec 2025 reached 0.4, down 42.84%, while the annual FY2025 figure was 0.4, 42.84% down from the prior year.
  • Equity Ratio reached 0.4 in Q4 2025 per LCTX's latest filing, up from 0.25 in the prior quarter.
  • Across five years, Equity Ratio topped out at 0.92 in Q2 2021 and bottomed at 0.25 in Q3 2025.
  • Average Equity Ratio over 5 years is 0.64, with a median of 0.63 recorded in 2023.
  • Peak YoY movement for Equity Ratio: grew 12.76% in 2024, then crashed 63.35% in 2025.
  • A 5-year view of Equity Ratio shows it stood at 0.91 in 2021, then plummeted by 36.18% to 0.58 in 2022, then grew by 5.55% to 0.61 in 2023, then increased by 12.76% to 0.69 in 2024, then tumbled by 42.84% to 0.4 in 2025.
  • Per Business Quant database, its latest 3 readings for Equity Ratio were 0.4 in Q4 2025, 0.25 in Q3 2025, and 0.52 in Q2 2025.